This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Hemispherx Announces Biosecurity Program To Potentially Reduce Pandemic Influenza Threat

PHILADELPHIA, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced that at the Options for the Control of Influenza VIII Conference in Cape Town, South Africa held 5-10 September, 2013, that a scientific advisor to Hemispherx, Professor Dr. Juergen A. Richt, DVM, Ph.D., Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Regents Distinguished Professor at Kansas State University, and an Eminent Scholar of Kansas Bioscience Association (KBA), described his experiments in human lung cells evidencing that Alferon N Injection ®, the only multi-species, natural interferon approved in the U.S. for the treatment of human refractory HPV genital warts, is biologically active, in low doses, against various classes of viruses occurring naturally in animals and humans.

The increasing prevalence of oseltamivir-resistant Influenza A viruses (IAVs), particularly H7N9, has been widely reported and is due in large part to the fact that just a single-step mutation in the neuraminidase (NA) gene of this genetically unstable virus makes it resistant to oseltamivir (Tamiflu ®). Dr. Richt reported on influenza genome instability " Viral reassortment and transmission after co-infection of pigs with classical H1N1 and triple-reassortant H3N2 swine influenza viruses" in 2010 in the peer-reviewed Journal of General Virology, an international journal.

The results of the recent Kansas State University experiments, coupled with Dr. Richt's work on reassortment and other published studies, set the stage for evaluating the possibility that mutational changes and reassortment could be prevented in animals by the use of type I interferon and/or a type I interferon inducer.

Professor Richt's diverse experimental program, sponsored in part by the U.S. Department of Homeland Security, National Institutes of Health, European Union, U.S. Department of Agriculture, and private entities, focuses on molecular mechanisms and pathogenesis of emerging pathogens in livestock populations as a critical first step in promoting and causing human disease, including various zoonotic viruses such as highly pathogenic influenza viruses, H7N9 or H5N1(i.e. zoonotic agents).

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,113.54 +61.81 0.36%
S&P 500 1,983.53 +9.90 0.50%
NASDAQ 4,456.0160 +31.3120 0.71%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs